Zanubrutinib-rituximab followed by shortened chemoimmunotherapy as frontline treatment for mantle cell lymphoma (CHESS): a phase II trial.

What was studied

This mid-stage trial, called CHESS, tested a new plan for mantle cell lymphoma (MCL). The patients had no earlier treatment. They got zanubrutinib plus rituximab for up to 12 cycles. Those with a complete response, or whose disease grew, then got R-DHAOx chemotherapy. Patients in complete response after that got zanubrutinib for one year. The main goal was the complete response rate after the first part.

What they found

Most patients had a complete response after the first part. Most still had one after the chemotherapy part. Blood-related side effects were the most common. These were low neutrophil and platelet counts. They were more frequent in the chemotherapy part.

What it means for patients

The authors say zanubrutinib-rituximab followed by shortened R-DHAOx works well as first treatment for MCL. They say safety was manageable. They say the plan allows fewer chemotherapy cycles. They say it needs validation in randomized trials.

Why it is not certain yet

This was a mid-stage trial. The abstract describes no comparison group. Blood-related side effects were common. The authors say randomized trials are needed.

Source

Zanubrutinib-rituximab followed by shortened chemoimmunotherapy as frontline treatment for mantle cell lymphoma (CHESS): a phase II trial.

We restate facts from the source record in our own words. The original wording belongs to its publisher.